Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.39 |
| ▸ | AKT2 | P31751 | 16/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 16/20 | 0.39 |
| ▸ | AHCY | P23526 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12288914 | 1.00 | AKT1 (0.39) | AKT1AKT2AKT3AHCYPIK3CA | |
| SCHEMBL12293385 | 1.00 | AKT1 (0.39) | AKT1AKT2AKT3AHCYPIK3CA | |
| SCHEMBL12293042 | 1.00 | AKT1 (0.39) | AKT1AKT2AKT3AHCYPIK3CA | |
| SCHEMBL12293083 | 1.00 | AKT1 (0.39) | AKT1AKT2AKT3AHCYPIK3CA | |
| SCHEMBL17771686 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL12323867 | 0.80 | LIMK1 (0.35) | AKT1AKT2AKT3AHCYLIMK1 | |
| SCHEMBL17771782 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17771781 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL12323863 | 0.80 | LIMK1 (0.35) | AKT1AKT2AKT3AHCYLIMK1 | |
| SCHEMBL12323054 | 0.80 | LIMK1 (0.35) | AKT1AKT2AKT3AHCYLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012135753-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135749-A2 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012088254-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087336-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-2402325-A2 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | Array Biopharma, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2399909-A1 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors | Array Biopharma, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011130654-A1 | FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| EP-2049501-B1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |